At AAIC 2026 in London, Lund University's Sebastian Palmqvist presented a Swedish real-world study of 1,310 patients with mild impairment or dementia and 165 physicians, as reported by the Alzheimer's Association in its AAIC primary-care release. An Alzheimer's blood test, which measures amyloid-beta and phosphorylated tau proteins in blood, raised primary-care diagnostic accuracy from 65% to 93%, essentially matching dementia specialists at 94%. That shift gives patients a practical opening. You can ask what your result rules in, what it rules out, and what should happen next.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the primary-care study show?
- What questions can I bring to my visit?
- How should I ask about a diagnosis change?
- Who are these blood tests meant for?
- What if I feel fine but worry about future risk?
What did the primary-care study show?
The study enrolled patients with mild impairment or dementia seen in primary and specialty care. Physicians made a diagnosis first, then saw blood-biomarker results and reconsidered.
After review, physicians changed diagnosis in about one-third of patients. They changed future care or testing plans in over half, according to the Alzheimer's Association.
What questions can I bring to my visit?
The test was most helpful for ruling out Alzheimer's disease in primary care. That makes questions about other causes and confirmation especially useful.
Bring a symptom timeline, medication list, and a family member when possible. Concrete details help the clinician interpret blood results in context.
- Could my result point away from Alzheimer's and toward another cause?
- Do my symptoms, exam, and history still fit Alzheimer's?
- Do I need PET imaging or spinal-fluid testing to confirm?
- How will this result change treatment, referrals, or follow-up?
How should I ask about a diagnosis change?
A result can move the working diagnosis toward or away from Alzheimer's. Ask what changed and why. Ask what diagnosis now fits best.
Also ask what stays the same. Daily safety, driving, work tasks, and support needs still matter while testing proceeds. Request a written plan for next tests, referrals, and the next check date.
Who are these blood tests meant for?
The U.S. Food and Drug Administration states in its first clearance notice that cleared tests are for adults already having cognitive signs and used with clinical workup, not general screening of healthy people nor standalone diagnosis. Ask whether you fit that use: persistent memory or thinking changes evaluated alongside history, exam, and cognitive testing.
The first cleared test, Fujirebio Lumipulse pTau217/beta-amyloid ratio, was cleared May 16, 2025 for ages 55 and older with symptoms in specialty care. C2N Diagnostics announced Aug. 20, 2026 in its PrecivityAD2 clearance announcement that PrecivityAD2 was cleared for symptomatic adults as young as 40.
What if I feel fine but worry about future risk?
A separate AAIC 2026 pooled study followed 2,684 cognitively unimpaired adults. Medscape, reporting on a JAMA study, noted in its p-tau217 risk report that very high plasma p-tau217 predicted about 38% risk of impairment within 5 years and 78% within 10 years, with each 1-SD increase raising risk 38%.
That finding does not make blood testing routine screening. Ask your clinician about validated risk factors, hearing and vision checks, sleep, mood, medications, vascular health, and when follow-up testing makes sense.
You Might Also Like
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Access, Cost, and Follow-Up Questions for Primary Care Patients
- Strengths-Based Dementia Care in the 2026 NIA Report: What the Report Means for Long-Distance Caregivers
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: What the Report Means for Long-Distance Caregivers
